Stephen J. Benkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stephen J. Benkovic has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Tsutomu Akama
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA94303, USA
4 shared publicationsYong-Kang Zhang
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA94303, USA
4 shared publicationsJacob J. Plattner
Anacor Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, CA 94303, USA
3 shared publicationsVincent Hernandez
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA94303, USA
2 shared publicationsAgnes Lau
Anacor Pharmaceuticals Inc., 1060 East Meadow Circle, Palo Alto, California 94303
1 shared publicationCharles Z Ding
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA94303, USA
1 shared publication
Latest Publications
- 7 February 2011
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 40 (8) , 4279-4285
Boron-containing inhibitors of synthetases
The use of boron in small-molecule pharmaceuticals is increasing. Boron's ubiquitous occurrence in nature and the recent success of a boronic acid drug (Velcade®) in the clinic have alleviated many concerns over its use in pharmaceuticals. In addition, the unique physicochemical properties of boronic acids make them an attractive addition to the medicinal chemists toolbox. This tutorial review will discuss these properties and potential benefits for anyone interested in finding novel enzyme inhibitors. An exceptional class of boronic acids, the oxaboroles, will be highlighted and their properties and uses will be discussed in detail. Finally, the current paradigm for the reaction of boronic acids with enzyme nucleophiles will be summarized.
- 7 February 2011
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 40 (8) , 4279-4285
Boron-containing inhibitors of synthetases
The use of boron in small-molecule pharmaceuticals is increasing. Boron's ubiquitous occurrence in nature and the recent success of a boronic acid drug (Velcade®) in the clinic have alleviated many concerns over its use in pharmaceuticals. In addition, the unique physicochemical properties of boronic acids make them an attractive addition to the medicinal chemists toolbox. This tutorial review will discuss these properties and potential benefits for anyone interested in finding novel enzyme inhibitors. An exceptional class of boronic acids, the oxaboroles, will be highlighted and their properties and uses will be discussed in detail. Finally, the current paradigm for the reaction of boronic acids with enzyme nucleophiles will be summarized.
- 15 December 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (24) , 7493-7497
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease
- 15 December 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (24) , 7493-7497
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease
- Top Cited Papers
- 21 October 2009
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 1 (7) , 1275-1288
Therapeutic Potential of Boron-Containing Compounds
Relative to carbon, hydrogen, nitrogen and oxygen, very little is currently known about boron in therapeutics. In addition, there are very few boron-containing natural products identified to date to serve as leads for medicinal chemists. Perceived risks of using boron and lack of synthetic methods to handle boron-containing compounds have caused the medicinal chemistry community to shy away from using the atom. However, physical, chemical and biological properties of boron offer medicinal chemists a rare opportunity to explore and pioneer new areas of drug discovery. Boron therapeutics are emerging that show different modes of inhibition against a variety of biological targets. With one boron-containing therapeutic agent on the market and several more in various stages of clinical trials, the occurrence of this class of compound is likely to grow over the next decade and boron could become widely accepted as a useful element in future drug discovery.
- 21 October 2009
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 1 (7) , 1275-1288
Top Cited PapersTherapeutic Potential of Boron-Containing Compounds
Relative to carbon, hydrogen, nitrogen and oxygen, very little is currently known about boron in therapeutics. In addition, there are very few boron-containing natural products identified to date to serve as leads for medicinal chemists. Perceived risks of using boron and lack of synthetic methods to handle boron-containing compounds have caused the medicinal chemistry community to shy away from using the atom. However, physical, chemical and biological properties of boron offer medicinal chemists a rare opportunity to explore and pioneer new areas of drug discovery. Boron therapeutics are emerging that show different modes of inhibition against a variety of biological targets. With one boron-containing therapeutic agent on the market and several more in various stages of clinical trials, the occurrence of this class of compound is likely to grow over the next decade and boron could become widely accepted as a useful element in future drug discovery.
- 1 December 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (23) , 5963-5967
Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases
- 1 December 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (23) , 5963-5967
Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases
- 27 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (15) , 4447-4450
Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
A structure−activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.
- 27 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (15) , 4447-4450
Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
A structure−activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.